Teva launches generic AndroGel
Teva is introducing its generic AndroGel (testosterone gel 1.62%).
Testosterone gel 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: congenital or acquired primary hypogonadism and congenital or acquired hypogonadotropic hypogonadism. It is a Schedule III controlled substance.
Testosterone gel 1.62% had a market value of more than $911 million, according to February 2019 IQVIA data.
Testosterone gel 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: congenital or acquired primary hypogonadism and congenital or acquired hypogonadotropic hypogonadism. It is a Schedule III controlled substance.
Testosterone gel 1.62% had a market value of more than $911 million, according to February 2019 IQVIA data.